Claims for Patent: 6,723,340

Summary for Patent: 6,723,340

Title:	Optimal polymer mixtures for gastric retentive tablets
Abstract:	Unit dosage form tablets for the delivery of pharmaceuticals are formed of the pharmaceutical dispersed in a solid unitary matrix that is formed of a combination of poly(ethylene oxide) and hydroxypropyl methylcellulose. The combination offers unique benefits in terms of release rate control and reproducibility while allowing both swelling of the tablet to effect gastric retention and gradual disintegration of the tablet to clear the tablet from the gastrointestinal tract after release of the drug has occurred.
Inventor(s):	Gusler; Gloria (Cupertino, CA), Berner; Bret (El Granada, CA), Chau; Mei (Sunnyvale, CA), Padua; Aimee (Daly City, CA)
Assignee:	DepoMed, Inc. (Menlo Park, CA)
Application Number:	10/029,134
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,723,340
Patent Claims:	1. A controlled-release tablet for releasing a drug into at least a portion of a region defined by the stomach and the upper gastrointestinal tract, said tablet comprising a solid monolithic matrix with said drug dispersed therein, said matrix comprising a combination of poly(ethylene oxide) and hydroxypropyl methylcellulose at a weight ratio that causes said matrix to swell upon contact with gastric fluid to a size large enough to provide gastric retention, wherein; said drug has a solubility in water that exceeds one part of said drug per ten parts of water, by weight, and wherein; said poly(ethylene oxide) has a viscosity average molecular weight of from about 2,000,000 to about 10,000,000 daltons, and wherein said hydroxypropyl methylcellulose has a viscosity of from about 4,000 centipoise to about 200,000 centipoise, measured as a 2% solution in water. 2. A controlled-release tablet in accordance with claim 1 in which said matrix swells by at least about 20% of its original size within 30 minutes upon immersion in gastric fluid to reach at least about 90% of its maximum size within 8 hours. 3. A controlled-release tablet in accordance with claim 1 wherein said hydroxypropyl methylcellulose has a viscosity of from about 50,000 centipoise to about 200,000 centipoise, measured as a 2% solution in water. 4. A controlled-release tablet in accordance with claim 1 said poly(ethylene oxide) has a viscosity average molecular weight of from about 4,000,000 to about 7,000,000 daltons, and said hydroxypropyl methylcellulose has a viscosity of from about 80,000 centipoise to about 120,000 centipoise, measured as a 2% solution in water. 5. A controlled-release tablet in accordance with claim 1 in which said drug has a solubility in water that exceeds one part of said drug per three parts of water, by weight. 6. A controlled-release tablet for releasing a drug into at least a portion of a region defined by the stomach and the upper gastrointestinal tract, said tablet comprising a solid monolithic matrix with said drug dispersed therein, said matrix comprising a combination of poly(ethylene oxide) and hydroxypropyl methylcellulose at a weight ratio that causes said matrix to swell upon contact with gastric fluid to a size large enough to provide gastric retention, wherein; said drug has a solubility in water that is less than one part of said drug per ten parts of water, by weight, said poly(ethylene oxide) has a viscosity average molecular weight of from about 100,000 to about 5,000,000 daltons, and said hydroxypropyl methylcellulose has a viscosity of from about 1,000 centipoise to about 100,000 centipoise, measured as a 2% solution in water. 7. A controlled-release tablet in accordance with claim 6 said poly(ethylene oxide) has a viscosity average molecular weight of from about 500,000 to about 2,500,000 daltons, and said hydroxypropyl methylcellulose has a viscosity of from about 4,000 centipoise to about 30,000 centipoise, measured as a 2% solution in water. 8. A controlled-release tablet in accordance with claim 7 in which said drug has a solubility in water ranging from about 0.05% to about 10% by weight. 9. A controlled-release tablet in accordance with claim 7 in which said drug has a solubility in water ranging from about 0.01% to about 5% by weight. 10. A controlled-release tablet in accordance with claim 1 in which the weight ratio of said poly(ethylene oxide) to hydroxypropyl methylcellulose is within the range of from about 1:2 to about 2:1. 11. A controlled-release tablet in accordance with claim 1 in which the weight ratio of said poly(ethylene oxide) and hydroxypropyl methylcellulose in combination constitute from about 15% to about 90% by weight of said dosage form. 12. A controlled-release tablet in accordance with claim 1 in which said poly(ethylene oxide) and hydroxypropyl methylcellulose in combination constitute from about 30% to about 65% by weight of said dosage form. 13. A controlled-release tablet in accordance with claim 1 in which said poly(ethylene oxide) and hydroxypropyl methylcellulose in combination constitute from about 40% to about 50% by weight of said dosage form. 14. A controlled-release tablet in accordance with claim 1 in which said drug is a member selected from the group consisting of metformin hydrochloride, losartan potassium, sodium valproate, valproic acid, and gabapentin. 15. A controlled-release tablet in accordance with claim 14 in which said drug is metformin hydrochloride. 16. A controlled-release tablet in accordance with claim 14 in which said drug is losartan potassium. 17. A controlled-release tablet in accordance with claim 9 in which said drug is ciprofloxacin. 18. A controlled-release tablet in accordance with claim 14 in which said drug is gabapentin. 19. A controlled-release tablet in accordance with claim 6 in which said matrix swells by at least about 20% of its original size within 30 minutes upon immersion in gastric fluid to reach at least about 90% of its maximum size within 8 hours.